

February 25, 2025

House Committee on Behavioral Health and Health Care  
900 Court Street NE  
Salem, OR 97301

**RE: HB 3082 Reporting Obligations for PAP Programs**

Dear Chair Nosse, Vice Chairs Javadi and Nelson, and Members of the Committee:

Thank you for the opportunity to share our support for House Bill 3082. Kaiser Permanente exists to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We serve over 616,000 members in Oregon and Southwest Washington who access coverage through a variety of plans spanning the commercial, Medicaid and Medicare markets.

Kaiser Permanente was pleased to support House Bill 4005, The Prescription Drug Price Transparency Act, when it passed in 2018 with broad bipartisan support. Among other provisions, HB 4005 (2018) required drug manufacturers to report the number of people who use a manufacturer prescription assistance program (PAP) when the price of a drug increases by 10 percent or more over the course of the previous year.

HB 3082 goes one step further by requiring drug manufacturers to report the number of people who use a PAP, regardless of price increases. In 2023, the Oregon Drug Price Transparency Program only received information on 18 patient assistance programs from eight manufacturers<sup>1</sup>. This limited information is only a small fraction of the estimated more than 200 patient assistance programs available and is not enough for meaningful analysis.

The increased transparency that HB 3082 will provide is necessary to help the Legislature and Oregonians understand how PAP programs impact prescription drug costs and availability. PAPs often steer patients toward expensive brand-name drugs where generics or lower priced multi-source drugs are available. Instead of relying upon coupons, discount cards, and other PAPs to fill gaps in coverage and address affordability, we recommend the Legislature explore policies to hold drug manufacturers accountable for their high prices.

We encourage your support of HB 3082 and look forward to further discussions.

Sincerely,

Jen Lewis-Goff  
Government Affairs Director

---

<sup>1</sup> <https://dfr.oregon.gov/drugtransparency/Documents/20231207-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2023.pdf>